Cue Biopharma, Inc.
CUENASDAQHealthcare● Active
$29.67
+$0.59(+2.03%)
Market Cap$77970624
P/E Ratio—
52W High$41.42
52W Low$4.98
Cue Biopharma, Inc. (CUE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CUE · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $27.47M | $9.29M | $5.49M | $1.25M | $14.94M |
| Cost of Revenue | $0.00M | $0.00M | $38.10M | $0.00M | ($1.78M) |
| Gross Profit | $27.47M | $9.29M | ($32.61M) | $1.25M | $16.72M |
| Gross Margin %(computed) | 100.00% | 100.00% | -593.93% | 100.00% | 111.90% |
| Operating Expenses | |||||
| R&D Expenses | $37.74M | $36.30M | $40.80M | $38.58M | $41.35M |
| G&A Expenses | $16.24M | $14.59M | $16.68M | $16.17M | $17.31M |
| Total Operating Expenses | $53.99M | $50.79M | $19.54M | $54.47M | $60.43M |
| Operating Income | ($26.52M) | ($41.50M) | ($52.15M) | ($53.23M) | ($43.71M) |
| Operating Margin %(computed) | -96.56% | -446.86% | -949.89% | — | -292.56% |
| Interest Income | $0.81M | $1.62M | $2.66M | $0.93M | $0.05M |
| Interest Expense | $0.36M | $0.80M | $1.25M | $0.71M | $0.00M |
| Income Before Tax | ($26.10M) | ($40.67M) | ($50.73M) | ($53.01M) | ($43.67M) |
| Income Tax Expense | $0.50M | $0.00M | $0.00M | $0.00M | $0.49M |
| Net Income | ($26.60M) | ($40.67M) | ($50.73M) | ($53.01M) | ($44.16M) |
| Net Margin %(computed) | -96.85% | -437.97% | -924.10% | — | -295.56% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-8.40 | $-21.60 | $-33.30 | $-44.70 | $-42.30 |
| Wtd Avg Shares | 3.16M | 1.88M | 1.53M | 1.19M | 1.04M |
| EBITDA | ($22.27M) | ($37.53M) | ($46.05M) | ($50.49M) | ($45.44M) |
| EBITDA Margin %(computed) | -81.06% | -404.09% | -838.83% | — | -304.15% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Cue Biopharma, Inc. data
About Cue Biopharma, Inc. (CUE) Income Statement
Cue Biopharma, Inc. (CUE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CUE reported revenue of $0.03B, gross profit of $0.03B (gross margin 100.00%), and net income of ($0.03B) — a net profit margin of -96.85%.
Frequently asked questions
CUE · 4 questionsCue Biopharma, Inc. (CUE) reported revenue of $0.03B for 2025, up 195.7% year-over-year.
CUE revenueCUE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09